3,4-Methylenedioxyphenethylamine
This is an old revision of this page, as edited by DePiep (talk | contribs) at 18:04, 2 April 2016 (Remove redundant parameters InChI, InChIKey (StdInChI, StdInChIKey are used). See Talk (via AWB script)). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.
This article needs additional citations for verification. Please help improve this article by adding citations to reliable sources. Unsourced material may be challenged and removed. Find sources: "3,4-Methylenedioxyphenethylamine" – news · newspapers · books · scholar · JSTOR (July 2009) (Learn how and when to remove this message) |
Clinical data | |
---|---|
Other names | 1,3-benzodioxolyl-5-ethanamine; 3,4-methylenedioxy-2-phenylethylamine |
Pregnancy category |
|
Routes of administration | Various |
Legal status | |
Legal status | |
Pharmacokinetic data | |
Bioavailability | ? |
Metabolism | ? |
Elimination half-life | ? |
Excretion | ? |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
DrugBank |
|
ChemSpider | |
CompTox Dashboard (EPA) | |
ECHA InfoCard | 100.014.601 |
Chemical and physical data | |
Formula | C9H11NO2 |
Molar mass | 165.18914 g/mol g·mol−1 |
3D model (JSmol) | |
| |
| |
(verify) |
3,4-Methylenedioxyphenethylamine (MDPEA), also known as homopiperonylamine, is a substituted phenethylamine formed by adding a methylenedioxy group to phenethylamine. It is structurally similar to MDA, but without the methyl group at the alpha position.
According to Alexander Shulgin in his book PiHKAL, MDPEA appears to be biologically inactive. This is likely because of extensive first-pass metabolism by the enzyme monoamine oxidase. However, if MDPEA were either used in high enough of doses (e.g., 1-2 grams), or in combination with a monoamine oxidase inhibitor (MAOI), it is probable that it would become sufficiently active, though it would likely have a relatively short duration of action. This idea is similar in concept to the use of selective MAOA inhibitors and selective MAOB inhibitors in augmentation of dimethyltryptamine (DMT) and phenethylamine (PEA), respectively.
See also
References
- ^ = WDU20111050614 "Ustawa z dnia 15 kwietnia 2011 r. o zmianie ustawy o przeciwdziałaniu narkomanii ( Dz.U. 2011 nr 105 poz. 614 )". Internetowy System Aktów Prawnych. Retrieved 17 June 2011.
{{cite web}}
: Check|url=
value (help)
External links
Phenylalkyl- amines (other than cathinones) |
|
---|---|
Cyclized phenyl- alkylamines | |
Cathinones | |
Tryptamines | |
Chemical classes |
α1 |
| ||||
---|---|---|---|---|---|
α2 |
| ||||
β |
| ||||
Phenethylamines |
|
---|---|
Amphetamines |
|
Phentermines |
|
Cathinones |
|
Phenylisobutylamines | |
Phenylalkylpyrrolidines | |
Catecholamines (and close relatives) |
|
Miscellaneous |
|
This drug article relating to the nervous system is a stub. You can help Wikipedia by expanding it. |
- CS1 errors: URL
- Articles needing additional references from July 2009
- All articles needing additional references
- Articles with short description
- Short description is different from Wikidata
- Drugs with non-standard legal status
- ECHA InfoCard ID from Wikidata
- Chem-molar-mass both hardcoded and calculated
- Infobox-drug molecular-weight unexpected-character
- Articles without EBI source
- Articles without KEGG source
- Articles without UNII source
- Drugs missing an ATC code
- All stub articles